A Pill to Fight Obesity Is on the Verge of Approval – Gizmodo
A Pill to Fight Obesity Is on the Verge of Approval Gizmodo Eli Lilly’s oral GLP-1 pill may help people with Type 2 diabetes lose ‘significant’ weight, study finds ABC News Eli Lilly Ready to Seek Obesity Pill Green Light After Study Hits Goals The Wall Street Journal Eli Lilly’s weight loss pill orforglipron clears its latest trial, […]
Can WeightWatchers stay relevant when everyone is on diet drugs?
GLP-1 medications could be the group’s death knell — or grant it a new lease on life
‘Derma, Physio, Ayurveda…Everyone Prescribing Weight-Loss Drugs’: IMA Chief Flags Misuse Of Mounjaro, Wegovy
Dr Dilip Bhanushali said GLP‑1 drugs should be restricted to endocrinologists, general physicians, and diabetologists to curb misuse & prevent side effects seen in Western markets
Do GLP-1 drugs shrink your muscles? New study explains the risks and what to do
GLP-1 receptor agonists are transforming obesity and diabetes care, but may reduce skeletal muscle mass, raising concerns about sarcopenic obesity. This comprehensive review explores the mechanisms, clinical implications, and mitigation strategies, including exercise, protein intake, and adjunct therapies.
Lilly’s oral GLP-1 respectable vs. injectables, filing soon
Eli Lilly and Co.’s regulatory ducks are lined up nicely with the latest positive top-line results from the phase III Attain-2 trial testing orforglipron, an oral glucagon-like peptide 1 (GLP-1) receptor agonist, in adults with obesity or overweight and type 2 diabetes.
Eli Lilly’s Oral GLP-1 Orforglipron Successful in Third Phase 3 Trial
What You Should Know: – Eli Lilly and Company has announced positive topline results from its Phase 3 ATTAIN-2 trial, which evaluated orforglipron, an investigational oral GLP-1 receptor agonist, in adults with obesity or overweight and type 2 diabetes. – All three doses of the drug met the primary and all key secondary endpoints, showing […]
Eli Lilly’s weight loss pill clears latest trial
US pharma giant Eli Lilly said its anti-obesity pill hit weight loss targets in a recent trial, boosting its efforts to compete in the expanding market. The findings help Lilly counter earlier trial results that underwhelmed investors, showing how closely the market is watching the development of anti-obesity pills, which would cost less than current […]
Lilly's experimental drug shows positive results for weight loss in diabetes patients
LOS ANGELES, Aug. 26 (Xinhua) — U.S. pharmaceutical company Lilly announced Tuesday that its experimental oral GLP-1 receptor agonist, orforglipron, achieved positive results in a Phase 3 trial targeting adults with overweight and type 2 diabetes. Read full story
This Slimy Food Works Like Ozempic — Without the Side Effects | Dr. Mandell
Most people avoid okra because of its slimy texture, but that very slime — called mucilage — may be one of nature’s most powerful medicines. In this video, I’ll reveal how okra mimics the same pathway as Ozempic and other GLP-1 drugs, naturally balancing blood sugar, lowering cholesterol, curbing appetite, and feeding your gut microbiome. […]
GLP-1 Receptor Agonist Use Linked to Reduced Overall Risk for Cancer in Adults With Obesity
TUESDAY, Aug. 26, 2025 — For adults with obesity, glucagon-like peptide-1 receptor agonist (GLP-1 RA) use is associated with a reduced overall risk for cancer, including lower risks for endometrial, ovarian, and meningioma cancers, according to a…